10-K: Cassava Sciences Navigates Setbacks in Alzheimer's Program, Shifts Focus to TSC-Related Epilepsy in 2024 10-K Filing

Cassava Sciences reports discontinuation of Alzheimer's clinical trials, a settlement with the SEC, and a strategic shift towards Tuberous Sclerosis Complex (TSC)-related epilepsy in its 2024 10-K filing.

Summary

• Cassava Sciences, a clinical-stage biotechnology company, focuses on central nervous system disorders.
• The company discontinued its Phase 3 clinical trials for simufilam in Alzheimer's disease after the RETHINK-ALZ study failed to meet its endpoints.
• Top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
• The company plans to analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data, with top-line results expected late first-quarter/early second-quarter 2025.
• Cassava is shifting focus to Tuberous Sclerosis Complex (TSC)-related epilepsy, supported by preclinical research and a license agreement with Yale University.
• The company entered into a License Agreement with Yale on February 26, 2025, granting exclusive worldwide rights to develop and commercialize simufilam for TSC-related epilepsy.
• The company settled with the SEC for $40 million regarding disclosures related to a Phase 2b study.
• The company is cooperating with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang.
• A workforce reduction of 33% was announced on January 7, 2025, to align resources with strategic goals.
• The company had cash and cash equivalents of $128.6 million as of December 31, 2024, expected to fund operations for at least the next 12 months.
• Research and development expenses were $69.6 million for the year ended December 31, 2024, compared to $89.4 million in 2023 and $68.0 million in 2022.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's a shift towards a new therapeutic area (TSC-related epilepsy) and existing cash reserves, the failure of the Alzheimer's program and the SEC settlement weigh negatively. The sentiment is cautiously optimistic but tempered by past setbacks.

Positives

• Cassava Sciences has shifted its focus to TSC-related epilepsy, potentially opening a new avenue for simufilam.
• The company secured a license agreement with Yale University, providing exclusive worldwide rights to develop and commercialize simufilam for TSC-related epilepsy.
• Cassava Sciences has $128.6 million in cash and cash equivalents as of December 31, 2024, which is expected to fund operations for at least the next 12 months.

Negatives

• The Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
• The company discontinued the Phase 3 REFOCUS-ALZ study and Open Label Extension study.
• The company paid a civil monetary penalty of $40 million in November 2024 as part of a settlement with the SEC resolving the SEC investigation of the Companys disclosures regarding its Phase 2b Study and related matters.
• A workforce reduction of 33% was announced on January 7, 2025, to align resources with strategic goals.

Risks

• The company faces risks associated with the development and regulatory approval of new drugs, particularly in central nervous system disorders.
• The company's future success is heavily dependent on the success of simufilam, which is still under development.
• The company has a limited operating history and no history of product approvals for commercial sale.
• The company may encounter substantial delays in clinical studies or may not be able to conduct or complete clinical studies on the timelines expected.
• The company relies on third parties for the supply and manufacture of materials for its product candidates, which carries the risk of insufficient supply or unacceptable costs.
• The company is subject to lawsuits and governmental investigations and inquiries, which could have a material adverse effect on its operating results and financial condition.
• The company may not be successful in obtaining and maintaining sufficient patent protection for its product candidates.
• The company's internal computer systems, or those used by third parties on whom it relies, may fail or suffer other breakdowns, cyberattacks, or information security breaches.

Future Outlook

The company expects to release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025 and will evaluate the results to determine the next steps for its Alzheimer's program. The company intends to conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilams potential as a treatment for TSC-related seizures.

Management Comments

• The Company intends to analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data.
• Following the release of the topline REFOCUS-ALZ results, the Company intends to evaluate the results and determine the next steps for the future advancement, if any, of its Alzheimers program.

Industry Context

The Alzheimer's disease treatment landscape is highly competitive, with several approved therapies and numerous companies pursuing new treatments. The company faces competition from established pharmaceutical companies with greater resources and expertise. The TSC-related epilepsy treatment landscape includes traditional anti-seizure medications and disease-specific ASMs, but a significant portion of patients remain inadequately controlled, highlighting the need for additional therapeutic options.

Comparison to Industry Standards

• The document mentions Eli Lilly's Kisunla (donanemab-azbt), Biogen's aducanumab (discontinued), and Eisai and Biogen's lecanemab (Leqembi) as competitors in the Alzheimer's disease market.
• These drugs are currently delivered by infusion, while simufilam was being developed as an oral treatment.
• In TSC-related epilepsy, the document mentions Afinitor Disperz (everolimus) and Epidiolex (cannabidiol) as approved treatments, but notes that they are not effective for all patients and can have significant side effects.

Management Changes

Corporate Governance

Legal Proceedings

• The company is defending itself in a number of lawsuits, including securities class action and shareholder derivative actions.
• The Company, as well as two former senior employees of the Company, have been and may continue to be subject to governmental investigations and inquiries.
• On September 26, 2024, the Company announced that it had reached a settlement with the SEC resolving the SEC investigation of the Companys disclosures regarding its Phase 2b Study and related matters.
• On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Hoau-Yan Wang.
• On January 24, 2025, the Delaware Court of Chancery entered a Final Order and Judgment approving the Stipulation and dismissing an action related to the CIB Plan with prejudice.

Related Party Transactions

• Remi Barbier, former President and Chief Executive Officer, is receiving severance compensation equal to $1.23 million over twelve months following the Effective Date.
• Lindsay Burns, Ph.D., former SVP, Neuroscience, is receiving severance compensation equal to $0.5 million in quarterly installments over twelve months from July 16, 2024.
• The Company entered into a one-year consulting agreement with the Companys former SVP, Neuroscience, and will pay $500 per hour for such consulting services.

Stakeholder Impact

• Shareholders: The discontinuation of the Alzheimer's program and the SEC settlement may negatively impact shareholder value.
• Employees: The workforce reduction of 33% will impact affected employees.
• Patients: The discontinuation of the Alzheimer's program may impact patients who were participating in clinical trials or who were hoping for a new treatment option.
• Collaborators: The shift in focus to TSC-related epilepsy may impact existing collaborations and create new opportunities.

Next Steps

• Analyze the complete 52-week dataset from the REFOCUS-ALZ study, along with a large portion of 76-week data.
• Release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025.
• Evaluate the REFOCUS-ALZ results and determine the next steps for the future advancement, if any, of its Alzheimers program.
• Conduct exploratory preclinical studies in collaboration with the TSCA to better understand simufilams potential as a treatment for TSC-related seizures.
• Assess whether there is support for an IND application in respect of a proof-of-concept open-label clinical trial for simufilam in TSC-related epilepsy.

Key Dates